These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3007682)

  • 1. WR-2721 protects against the hematologic toxicity of cyclophosphamide.
    Phillips TL
    J Clin Oncol; 1986 Apr; 4(4):458. PubMed ID: 3007682
    [No Abstract]   [Full Text] [Related]  

  • 2. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial.
    Glover D; Glick JH; Weiler C; Hurowitz S; Kligerman MM
    J Clin Oncol; 1986 Apr; 4(4):584-8. PubMed ID: 3007686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I controlled trials of WR-2721 and cyclophosphamide.
    Glick JH; Glover D; Weiler C; Norfleet L; Yuhas J; Kligerman MM
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1777-80. PubMed ID: 6090370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy.
    Glover D; Fox KR; Weiler C; Kligerman MM; Turrisi A; Glick JH
    Pharmacol Ther; 1988; 39(1-3):3-7. PubMed ID: 2849130
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase I clinical trials of WR-2721 with alkylating agent chemotherapy.
    Glick JH; Glover DJ; Weiler C; Blumberg A; Nelson D; Yuhas JM; Kligerman M
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):575-80. PubMed ID: 6286556
    [No Abstract]   [Full Text] [Related]  

  • 6. Modification of radiosensitivity of bone marrow lymphocytes by WR-2721.
    Naruka K; Bhartiya HC
    Acta Oncol; 1987; 26(4):317-8. PubMed ID: 2825734
    [No Abstract]   [Full Text] [Related]  

  • 7. Protection of bone marrow by WR-2721 after fractionated irradiation.
    Coia LR; Brown DQ
    Int J Radiat Oncol Biol Phys; 1989 Oct; 17(4):908-9. PubMed ID: 2550401
    [No Abstract]   [Full Text] [Related]  

  • 8. Protection by WR-2721 of human bone marrow function following irradiation.
    Constine LS; Zagars G; Rubin P; Kligerman M
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1505-8. PubMed ID: 2428794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide.
    Woolley PV; Ayoob MJ; Smith FP; Dritschilo A
    J Clin Oncol; 1983 Mar; 1(3):198-203. PubMed ID: 6321681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials of WR-2721 and cis-platinum.
    Glover D; Grabelsky S; Fox K; Weiler C; Cannon L; Glick J
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1201-4. PubMed ID: 2541121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WR-2721: a chemotherapy and radiation-protective agent.
    Schein PS
    Cancer Invest; 1990; 8(2):265-6. PubMed ID: 2169331
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of WR 2721 on the efficacy of radiotherapy and chemotherapy of murine tumors.
    Clement JJ; Johnson RK
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):539-42. PubMed ID: 6286550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the outlook grey for WR-2721 as a clinical radioprotector?
    Denekamp J; Stewart FA; Rojas A
    Int J Radiat Oncol Biol Phys; 1983 Aug; 9(8):1247-9. PubMed ID: 6307942
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I/II trials of WR-2721 and cis-platinum.
    Glover D; Glick JH; Weiler C; Fox K; Turrisi A; Kligerman MM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1509-12. PubMed ID: 3019969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of WR-2721 in radiotherapy and/or chemotherapy.
    Yuhas JM; Spellman JM; Culo F
    Cancer Clin Trials; 1980; 3(3):211-6. PubMed ID: 6254681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A more general role for WR-2721 in cancer therapy.
    Yuhas JM
    Br J Cancer; 1980 May; 41(5):832-4. PubMed ID: 6252918
    [No Abstract]   [Full Text] [Related]  

  • 17. Modification by WR 2721 of the response to chemotherapy of tumours and normal tissues in the mouse.
    Twentyman PR
    Br J Cancer; 1983 Jan; 47(1):57-63. PubMed ID: 6295428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-2-(3-Aminopropylamino)ethyl phosphorothioic acid (WR-2721) in primary hyperparathyroidism.
    Morita M; Higashi K; Tajiri J; Sato T
    Ann Intern Med; 1985 Dec; 103(6 ( Pt 1)):961. PubMed ID: 2998254
    [No Abstract]   [Full Text] [Related]  

  • 19. Need for studies on factors that influence radioprotection of solid tumors by WR-2721.
    Milas L
    Int J Radiat Oncol Biol Phys; 1984 Jan; 10(1):163-5. PubMed ID: 6321410
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide.
    Yuhas JM; Spellman JM; Jordan SW; Pardini MC; Afzal SM; Culo F
    Br J Cancer; 1980 Oct; 42(4):574-85. PubMed ID: 6254555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.